Troponin revisited 2008: assay performance

Area of Science:

• Clinical Chemistry
• Biomarker Assay Development
• Cardiovascular Diagnostics

Background:

• Cardiac troponin (cTn) assays are vital for diagnosing myocardial infarction.
• Current assays face challenges in pre-analytical, analytical, and post-analytical phases, impacting result accuracy.
• Existing imprecision levels (20% CV) exceed recommendations (10% CV) at the 99th percentile.

Purpose of the Study:

• To outline quality specifications for cardiac troponin (cTn) assays.
• To address pre-analytical, analytical, and post-analytical performance requirements.
• To guide the development and implementation of next-generation, highly sensitive cTn assays.

Main Methods:

• Review of pre-analytical factors (sample type, stability, handling) to prevent false positives.
• Analysis of analytical issues including sensitivity, imprecision, antibody specificity, interferences, and standardization.
• Evaluation of current assay performance (2nd gen cTnI, 4th gen cTnT) against recommended quality standards.

Main Results:

• Next-generation cTn assays are expected to have 10-fold lower upper reference limits.
• Monitoring ultra-low cTn concentrations requires specialized quality control and negative controls.
• Establishing accurate reference ranges necessitates cardio-healthy populations for differentiation.

Conclusions:

• Robust quality specifications are essential for both cTn assay manufacturers and clinical laboratories.
• Future assays demand enhanced analytical sensitivity and precision for reliable clinical decision-making.
• Close collaboration between laboratories and clinicians is vital for validating new, sensitive cTn assays.